Stem Cells Treatment of Complex Crohn's Anal Fistula
- Conditions
- Anal FistulaCrohn Disease
- Interventions
- Procedure: stem cells injection
- Registration Number
- NCT03466515
- Lead Sponsor
- University of Southern Denmark
- Brief Summary
A pilot study to investigate the safety and feasibility of stem cells treatment of complex anal fistula in patients with Crohn's disease.
- Detailed Description
Stem cells therapy in the management of soft tissue healing has been shown to be safe and feasible with encouraging short-term results both for crypto glandular and Crohns anal fistula. The long-term results are still insufficient but based on only a few studies conducted with small patient series and various techniques and type of stem cells. In the present study the patient's own adipose tissue derived regenerative cells (ADRCs) will be used. Traditionally the stem cells are injected into the fistula tract; however survival and retaining the stem cells in the fistula tract is problematic. Alternatively, one may apply stem cells enriched fatty tissue around and into the fistula tract. The aim of this project is to develop a method for treatment of patients with Crohns fistula. The results of conventional surgery are disappointing and followed by a high degree of recurrence and complications.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
- patients with Crohn's anal fistulas and> 18 yrs old.
- Signs of suppuration around the fistula
- Active intestinal Crohn disease not in remission
- Malignancy within 5 years
- Previous radiotherapy of the abdomen and pelvis
- BMI under 18.5
- Coagulopathy
- Fistula with side branches
- Low anal fistula
- Verified syphilis, HIV, or hepatitis on screening test.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description intervention stem cells injection Patients enrolled in the study will be treated for their anal fistula by surgical closure of the internal opening, debridement of the fistula and injection of patients own stem cells enriched fatty tissue around the fistula.
- Primary Outcome Measures
Name Time Method healing 6 months closure of the fistula with no secretions
- Secondary Outcome Measures
Name Time Method recurrence 6 months recurrence of the fistula
time to healing 6 months time required to healing of the fistula
radiological healing at 6 months Changes on MRI scanning
functional outcome 6 months changes in Wexner incontinence score
major adverse effects 6 months occurrence of infections, sepsis bleeding and allergy.
Trial Locations
- Locations (1)
Odense University Hospital
🇩🇰Odense, Denmark